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Abstract
Background: Gastrointestinal hormones regulate intestinal transit, control digestion, influence appetite and promote
satiety. Altered production or action of gut hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent
insulinotropic polypeptide (GIP) and peptide YY (PYY), may contribute to the biological basis of obesity and altered
glucose homeostasis. However, challenges in analytical methodology and lack of clarity on expected values for healthy
individuals have limited progress in this field. The aim of this study was to describe expected concentrations of gas-
trointestinal and pancreatic hormones in healthy volunteers following a standardized meal test (SMT) or 75 g oral
glucose tolerance test (OGTT).
Methods: A total of 28 healthy volunteers (12 men, 16 women; mean age 31.3 years; mean body mass index 24.9 kg/m2)
were recruited to attend a hospital clinic on two occasions. Volunteers had blood sampling in the fasting state and were
given, in randomized order, an oral glucose tolerance test (OGTT) and standardized mixed liquid meal test with
venepuncture at timed intervals for 4 h after ingestion. Analytical methods for gut and pancreatic hormones were
assessed and optimized. Concentrations of gut and pancreatic hormones were measured and used to compile ranges
of expected values.
Results: Ranges of expected values were created for glucose, insulin, glucagon, GLP-1, GIP, PYY and free fatty acids in
response to a standardized mixed liquid meal or OGTT. Intact proinsulin and C-peptide levels were also measured
following the OGTT.
Conclusions: These ranges of expected values can now be used to compare gut hormone concentrations between
healthy individuals and patient groups.
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The rising prevalence of nutritional disorders has led to
increased scientific interest in the mechanisms which
regulate nutrient disposal, appetite and satiety.
Hormones such as glucagon-like peptide-1 (GLP-1)
and peptide YY (PYY), which are released from the
gastrointestinal tract in response to nutrient ingestion,
may mediate satiety and reduce appetite.1,2 GLP-1- and
glucose-dependent insulinotropic polypeptide (GIP)
function as incretins, promoting the release of insulin
from the pancreas in response to a meal.3 The complex
relationships between gastrointestinal and pancreatic
hormones are now thought to regulate energy balance
and may be affected by diseases such as type 2 diabetes
mellitus (T2DM).4 Bariatric surgery, which provides an
effective method of long-term weight control, is asso-
ciated with increased postprandial concentrations of
GLP-1, PYY and improved glucose tolerance.5,6
However, the expected circulating concentrations of
many gastrointestinal and pancreatic hormones in
healthy individuals have yet to be established, yet are
essential for the interpretation of altered levels seen in
metabolic and gastrointestinal conditions.
Despite the high levels of interest in gut hormones,
progress in this field has been limited by the develop-
ment of robust analytical methods for their quantita-
tion in plasma. Many of these peptides are present in
picomolar concentrations and require highly sensitive
assays, which can measure concentrations as low as
1–10 pmol/L. Highly specific assays are also required,
as many peptides have important structural similarities.
Glucagon and oxyntomodulin, for example, differ only
at their C-termini and are indistinguishable using anti-
bodies that target the shared peptide sequence.7 A
number of commercially available assays have been
shown to be unfit for purpose.8,9 However, analytical
methodology and the concordance of results obtained
using different assays are improving. With this
advancement in methodology, it is now possible to
permit comparison of plasma peptide concentrations
in health and disease.
Concentrations of several gastrointestinal hormones
are altered after bariatric surgery,10 in individuals with
T2DM4 and after gestational diabetes.11 However,
expected concentrations of a comprehensive range of
gut hormones in healthy individuals have not been
described in depth. The aim of the current study was
to provide ranges of expected values using reliable and
readily-available assays for gastrointestinal and pan-
creatic hormones in healthy human subjects in the fast-
ing state and after both an oral glucose tolerance test




Healthy male and female volunteers aged 18–65 years
old were recruited using advertisements placed in
Addenbrooke’s Hospital and the University of
Cambridge. To fulfil the entry criteria, healthy volun-
teers needed to be free from chronic diseases and recent
acute conditions, such as infections, diarrhoea or con-
stipation, and have a body mass index (BMI) of
18–35 kg/m2. Healthy participants were either taking
no medication or were stable on medication that was
considered unlikely to interfere with the results of the
study. Participants with known pre-existing anaemia,
diabetes or endocrine disorders and pregnant or lactat-
ing women were excluded from this study. The study
was given ethical approval by the local research ethics
committee (13/EE/0195), and all participants gave full
written consent.
Study visits and stimulation tests
Participants attended a Clinical Research Facility at
09:00 h on two occasions following an overnight fast.
The evening before each visit, participants prepared for
themselves a standardized pasta meal containing 15%
protein, 30% fat and 55% carbohydrate which was
designed to provide 33% of their daily calorie require-
ment based on an estimation of their metabolic rate
and activity levels.12 After the meal, participants were
allowed free access to water but were asked to avoid
food, caffeinated and calorie-containing drinks over-
night for 12 h prior to the study visit.
Participants attended for two visits and received a
75 g OGTT and a SMT in randomized order (Table 1
for composition). Blood was taken at baseline and at
timed intervals (0, 15, 30, 45, 60, 90, 120, 150, 180, 210
and 240min) after the OGTT or SMT for analysis of
glucose, non-esterified-free fatty acids (FFA) and pan-
creatic and gut hormones. Participants were asked to
remain sedentary throughout the testing process.
The OGTT was produced using 82.5 g glucose
monohydrate (equivalent to 75 g pure glucose) which
was dissolved in 250mL chilled water, and a further
glass of 250mL water was given afterwards to wash
out the oral cavity. The SMT consisted of a 237mL
bottle of Ensure plus, a balanced nutritional supple-
ment containing 11 g fat (28%), 13 g protein (15%)
and 50 g carbohydrate (57%). Participants were also
given 250mL of water after the meal was consumed.
Each drink (OGTT or SMT) was consumed within a
5min time frame. Altogether, the OGTT and SMT
provided 300 and 350 kcals, respectively.
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Analytical methodology
All analyses were performed in the Core Biochemical
Assay Laboratory in Addenbrooke’s Hospital. The
analytical methods used with performance measures
are given in Table 2 (see supplemental information
for more details). All analyses demonstrated acceptable
linearity and recovery and passed standard quality con-
trol measures. Samples with known common interfer-
ences such as haemolysis, lipaemia and
hyperbilirubinaemia were excluded from this analysis.
Statistical analysis
Characteristics of participants are described as mean
(SD). A range of expected values was produced
using the non-parametric method as recommended by
the IFCC through the Clinical and Laboratory
Standards Institute (CLSI).13 The 2.5th and 97.5th per-
centiles were calculated to give an interval which
included 95% of values from this sample. Other
approaches, such as bootstrapping and robust methods
were not used in this study but may have some advan-
tages in a small sample.14
The appropriate assessment of outliers is important
in establishing ranges of expected values. Some outliers
were identified and were assessed for each individual
participant and each analyte. If any clear pathological
cause was evident, the outlier was removed. However,
in practice, the outliers could not be explained on the
basis of known pathology and were not excluded. Some
individuals were found to have elevated fasting glucose
and insulin concentrations. Although these findings are
suggestive of prediabetes, they are also extremely
common in the reference population, and these data
were therefore kept in the analysis.
Results
A total of 28 healthy volunteers were recruited (12
male, 16 female; Table 3). Most healthy volunteers
were aged 22–40 years (31.3 10.9 years) with a lean
body mass index 24.9 3.7 kg/m2. Participants had
normal haemoglobin, white cell count, alanine amino-
transferase (ALT), thyroid-stimulating hormone (TSH)
and creatinine at baseline with an HbA1c in the non-
diabetic range (33.6 3.7mmol/L).
Data from these 28 participants were used to create
ranges of expected values for glucose, insulin, gluca-
gon, total GLP-1, PYY, GIP and FFA before and
after an OGTT and SMT (see Figures 1 and 2;
Tables S1 and S2). C-peptide and intact proinsulin
were measured following an OGTT only (n¼ 20 par-
ticipants; Figure 2).
Discussion
In this study, ranges of expected values were provided
for glucose, insulin, glucagon, total GLP-1, PYY, GIP
and FFA in healthy volunteers in fasting and postpran-
dial circumstances, in response to both an OGTT and a
standardized mixed liquid meal. Ranges for intact pro-
insulin and C-peptide were produced in healthy volun-
teers following an OGTT. These ranges of expected
values provide reference values for comparison with
concentrations in various disease states in future stud-
ies. There is currently no standardized stimulation test
for the assessment of postprandial gut hormone con-
centrations. Previous studies have used a variety of
stimuli including standardized breakfasts, mixed
liquid meals, glucose and ice cream,15–19 which presents
considerable challenges in the comparison of findings.
Table 1. Nutritional contents of OGTT and Ensure plus standardized meal.
Nutrient Ensure Plus (standardized meal) 75 g OGTT
Volume 237 mL 250 mL
Energy content 350 kcal, 1464 kJ 300 kcal, 1255 kJ
57% from carbohydrate, 15% from
protein and 28% from fat.
100% from carbohydrate
Carbohydrates, g 50 75




(25–50% recommended daily intake)
Vitamins A, B1, B2, B6, B12, C,D,E,K,
biotin, pantothenic acid and folate.
0
Minerals
(8–60% recommended daily intake)
Calcium, iron, phosphorus, iodine,
magnesium, zinc, selenium, copper,
manganese, chromium, molybdenum,
chloride.
Unknown, depends on water mineral
content.
OGTT: oral glucose tolerance test.
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As gut hormone release is triggered by protein and fat,
as well as glucose, a mixed meal is generally a well-
tolerated and reliable stimulus of gut hormone secre-
tion. The liquid standardized meal used in the current
study circumvents the requirement for mechanical food
breakdown in the stomach, and is therefore suitable for
comparison with patient groups, such as postbariatric
or other gastrointestinal surgery. Oral glucose toler-
ance tests using a 75 g glucose bolus are frequently
used for the assessment of glucose metabolism, but
are not well tolerated after gastric bypass surgery.
To assess variability in gut hormone secretion, our
data suggest that sampling at 0 and 30min time-points
would encompass the majority of variability in hor-
mone measurements in healthy subjects, although a
longer period of sampling may be required in popula-
tions where gastric emptying is more variable and in
response to solid meal stimuli. At later time points, the
inhibitory effects of elevated GLP-1 and PYY concen-
trations on gastric emptying tend to reduce the rate of
nutrient delivery into the small intestine. This means
the gut hormone concentrations then become a com-
plex balance between the strength of the feedback con-
trol of gastric emptying, the quantity of nutrients still
awaiting digestion and absorption and the secretory
potential of the small intestine.
Gut hormone analysis was based on methods that
are routine within our laboratory and we have found to
be reliable in most circumstances. Detailed methodol-
ogy and performance data have been given for each
analyte (Table 2 and supplemental material). Many
other studies advocate the use of protease inhibitors
and DPP-IV inhibitors which can be added to blood
tubes prior to sampling or provided in the form of spe-
cialized pretreated tubes.20 DPP4 or protease inhibitor-
treated tubes provide results up to 20–30% higher for
some analytes,21 which reduces the need for high
analytical sensitivity and may increase analytical per-
formance. However, in this study, we chose specimen
preparation and processing techniques that minimize
degradation while using equipment and blood tubes
readily available in most health-care environments
and require no added reagents. Although rapid proc-
essing is essential for gut hormone and insulin analyses,
these sample preparation methods were found in this
study to be feasible both in the hospital research unit
and have been tested in a mobile laboratory in the field.
DPP4 inhibitors would be required for the measure-
ment of active GLP-1 concentrations, but in the cur-
rent study, we elected to assay total GLP-1 as a better
potential measure of the hormone secretory rate.
Choosing a suitable group of individuals in perfect
health for the development of ranges of expected values
is challenging. The study group used here were relative-
ly young and lean and were recruited using advertise-
ments in University and Hospital buildings. Although
most participants took no regular medication, several
of the female participants were on the oral contracep-
tive pill, and this may have influenced the results.
Gastrointestinal and pancreatic hormone concentra-
tions were not studied at different specified times
during the female menstrual cycle or in post-
menopausal women. Our study group were predomi-
nantly European and ethnic differences in GLP-1
responses have been previously identified.22 We did
not study diurnal variation in gut and pancreatic hor-
mones although all visits took place in the morning,
and for insulin, glucagon, GLP-1, PYY and GIP, diur-
nal changes are likely to be influenced primarily by
nutrient ingestion at mealtimes.7 Although hormone
concentrations can be influenced by age, gender and
obesity, the current study has inadequate sample size
to provide formal reference intervals or partitioned ref-
erence estimations for subgroups of the population.13
Despite its limitations, this study provides a compre-
hensive set of data for expected concentrations of gut
hormones in healthy human subjects. Our data show
reasonable consistency with other published work,
although direct comparison is difficult due to the vari-
ety of stimulation tests and analytical methods used.
For example, Vilsbøll et al. studied fasting and post-
prandial gut hormone responses in eight healthy indi-
viduals who had previously had a normal OGTT.23 A
260 kcal meal of bread, margarine and jam was given
with milk. For GLP-1, fasting concentrations of
15–20 pmol/L (50–66 pg/mL) were obtained and con-
centrations peaked at 30 pmol/L (99 pg/mL) after the
meal (1 pmol/L GLP-1¼ 3.297 pg/mL GLP-1). For
GIP, fasting concentrations were around 15 pmol/L
(66 pg/mL) with a peak concentration of 80–90 pm
(352–396 pg/mL) after the meal (1 pmol/L
GIP¼ 4.4 pg/mL GIP). Visbǿll’s population had
Table 3. Baseline characteristics of study participants.
Characteristics shown as mean (SD) for continuous variables and
n (%) for categorical variables.
Characteristic Mean (SD)
Sex, male 12/28 (42.9%)
Age (years at enrolment) 31.3 (10.9)
Body mass index kg/m2 24.9 (3.7)
Haemoglobin g/L 135 (12)
White cell count 109/L 6.1 (1.6)
Platelets 109/L 223 (47)
Creatinine lmol/L 80.1 (14.7)
ALT IU/L 30.6 (9.8)
TSH U/L 1.6 (0.6)
HbA1c mmol/mol 33.6 (3.7)
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lower concentrations of fasting and postprandial insu-
lin (fasting 15–20 pmol/L; peak 180 pmol/L) com-
pared with the population under investigation in the
current study, but participants had been prescreened
with an OGTT prior to enrolment and individuals
with a family history of diabetes were excluded.
Concentrations of fasting C-peptide in Visbǿll’s study
were 400 pmol/L with peak concentrations of
1500 pmol/L after the meal.23 In contrast, Alsalim
et al. studied 24 healthy lean volunteers who had a
meal of 511 kcal, consisting of a sirloin steak with pota-
toes, vegetables and sorbet.24 Concentrations of intact
Figure 1. Ranges of expected values for glucose, insulin, glucagon, intact proinsulin, C-peptide, GLP-1, PYY, GIP and FFA in the
fasting state and after a 75 g oral glucose tolerance test (OGTT). Note that intact proinsulin and C-peptide were measured at time-
points 0, 30, 60, 90, 120, 180 and 240minutes only on samples from 20 participants. The remaining analytes were measured on
samples from 28 participants.
FFA: free fatty acids; GLP-1: glucagon-like peptide-1; GIP: glucose-dependent insulinotropic polypeptide; LRL: lower range limit; 2.5th
percentile; PYY: peptide YY; URL: upper range limit; 97.5th percentile.
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GIP were 10 pmol/L (44 pg/mL) fasting and peaked at
around 75 pmol/L (330 pg/mL) postprandially. Insulin
concentrations were around 30 pmol/L fasting and
around 250 pmol/L postprandially. C-peptide concen-
trations were 300 pmol/L fasting and around
1000 pmol/L postprandially. Unfortunately, concentra-
tions of total GLP-1 and GIP were not reported.24 In
the current study, the use of a liquid meal, rather than
solid food, is likely to explain the more rapid increase
in gut hormones seen in comparison to Visbǿll and
Alsalim’s work.23,24
In the current study, glucagon concentrations after
the SMT generally exhibited a small transient eleva-
tion, and thereafter remained similar to baseline. This
likely reflects a complex balance between inhibitory
signals acting on pancreatic alpha cells, including glu-
cose and GLP-1, and stimulatory signals such as amino
acids. After the OGTT, we expected to see a less com-
plex picture, as glucagon should be predominantly sup-
pressed by the elevated glucose and GLP-1
concentrations. Indeed, in the majority of healthy vol-
unteers, post-OGTT glucagon concentrations reached
a nadir by 45 to 60min. A few participants (6/28), how-
ever, exhibited an elevated glucagon of >50% at some
point in the first hour. It is currently not clear whether
this represents a true increase in biologically active glu-
cagon from the pancreas, release of glucagon from the
intestine, or detection by the glucagon assay of longer
peptides containing the glucagon sequence that might
be released from the gut or pancreas. It is also possible
that under physiological conditions, the glucagon-
stimulating effects of GIP outweigh the glucagon-
suppressing effects of GLP-1.25,26 It has been proposed
that the gut can release glucagon under certain
Figure 2. Ranges of expected values for glucose, insulin, glucagon, GLP-1, PYY, GIP and FFA in the fasting state and after a
standardized meal test (SMT), based on measurements taken from 28 participants.
FFA: free fatty acids; GLP-1: glucagon-like peptide-1; GIP: glucose-dependent insulinotropic polypeptide; LRL: lower range limit; 2.5th
percentile; PYY: peptide YY; URL: upper range limit; 97.5th percentile.
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conditions, including following total pancreatectomy
where pancreatic release should be impossible,27 or
after Roux-en-Y gastric bypass surgery.28,29 However,
when GLP-1 secretion is high, some glucagon assays
cross-react with longer proglucagon-derived species
containing the glucagon sequence, particularly glicen-
tin, leading to debate over whether the gut ever releases
intact glucagon.30,31 In addition to these reports from
populations with altered pathology, and although we
were unable to find active glucagon in human intestinal
tissue by LC-MS,32 our data suggest that some healthy
people may also exhibit post-OGTT glucagon
elevation.
In conclusion, this comprehensive set of expected
values for fasting and postprandial gastrointestinal
and pancreatic hormone concentrations in healthy
human subjects facilitates future comparison between
healthy individuals and those with metabolic or endo-
crine disorders in response to an OGTT or standard-
ized liquid meal.
Acknowledgements
The authors wish to thank colleagues at the Core Biochemical Assay
Laboratory, Department of Clinical Biochemistry and the Wellcome Trust
Clinical Research Facility, Addenbrooke’s Hospital.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: This research was funded by the Wellcome Trust
(WT084210Z/07/Z and WT088357Z/09/Z) and the MRC
(MRC_MC_UU_12012/3). CLM is supported by the
Diabetes UK Harry Keen Intermediate Clinical Fellowship
(DUK-HKF 17/0005712) and the EFSD-Novo Nordisk
Foundation Future Leader’s Award (NNF19SA058974).
This research was supported by the NIHR Cambridge
Clinical Research Facility. This research was supported by
the NIHR Cambridge Clinical Research Facility and Core
Assay Biochemistry Laboratory.
Ethical approval





FMG, FR and CLM conceived the study and gained funding.
CLM was responsible for participant recruitment, data col-
lection and data analysis. HBL assisted in recruitment and
data collection. KB developed methods for gut hormone
analysis and analysed the samples. CLM wrote the first
draft of the manuscript and all authors reviewed and edited
the article and approved the final version for publication.
ORCID iD
Claire L Meek https://orcid.org/0000-0002-4176-8329
Supplemental material
Supplemental material for this article is available online.
References
1. Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in
protein-mediated satiation and body-weight regulation. Cell Metab 2006;
4: 223–233.
2. N€aslund E, Barkeling B, King N, et al. Energy intake and appetite are
suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes
Relat Metab Disord 1999; 23: 304–311.
3. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36:
a physiological incretin in man. Lancet 1987; 2: 1300–1304.
4. Vilsbøll T, Krarup T, Deacon CF, et al. Reduced postprandial concen-
trations of intact biologically active glucagon-like peptide 1 in type 2 dia-
betic patients. Diabetes 2001; 50: 609–613.
5. Laferrere B, Heshka S, Wang K, et al. Incretin levels and effect are mark-
edly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese
patients with type 2 diabetes. Diabetes Care 2007; 30: 1709–1716.
6. Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone
profiles following bariatric surgery favor an anorectic state, facilitate
weight loss, and improve metabolic parameters. Ann Surg 2006; 243:
108–114.
7. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87:
1409–1439.
8. Bak MJ, Wewer Albrechtsen NJ, Pedersen J, et al. Specificity and sensi-
tivity of commercially available assays for glucagon-like peptide-1 (GLP-
1): implications for GLP-1 measurements in clinical studies. Diabetes Obes
Metab 2014; 16: 1155–1164.
9. Bak MJ, Albrechtsen NW, Pedersen J, et al. Specificity and sensitivity of
commercially available assays for glucagon and oxyntomodulin measure-
ment in humans. Eur J Endocrinol 2014; 170: 529–538.
10. Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal
hormone responses, insulin sensitivity, and beta-cell function within 2
weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22:
1084–1096.
11. Forbes S, Moonan M, Robinson S, et al. Impaired circulating glucagon-
like peptide-1 response to oral glucose in women with previous gestational
diabetes. Clin Endocrinol (Oxf) 2005; 62: 51–55.
12. Schofield W. Predicting basal metabolic rate, new standards and review of
previous work. Hum Nutr Clin Nutr 1985; Suppl 1: 5–41.
13. al. WPeClinical and Laboratory Standards Institute: defining, establishing
and verifying reference intervals in the clinical laboratory. Approved
guideline. Third edition. CLSI document C28-A3., 2008.
14. Horn PS, Pesce AJ and Copeland BE. A robust approach to reference
interval estimation and evaluation. Clin Chem 1998; 44: 622–631.
15. Lewis HB, Ahern AL, Solis-Trapala I, et al. Effect of reducing portion size
at a compulsory meal on later energy intake, gut hormones, and appetite in
overweight adults. Obesity (Silver Spring) 2015; 23: 1362–1370.
16. Mans E, Serra-Prat M, Palomera E, et al. Sleeve gastrectomy effects on
hunger, satiation, and gastrointestinal hormone and motility responses
after a liquid meal test. Am J Clin Nutr 2015; 102: 540–547.
17. Korner J, Bessler M, Inabnet W, et al. Exaggerated glucagon-like peptide-
1 and blunted glucose-dependent insulinotropic peptide secretion are asso-
ciated with Roux-en-Y gastric bypass but not adjustable gastric banding.
Surg Obes Relat Dis 2007; 3: 597–601.
18. Faerch K, Torekov SS, Vistisen D, et al. GLP-1 response to oral glucose is
reduced in prediabetes, screen-detected type 2 diabetes, and obesity and
influenced by sex: the ADDITION-PRO Study. Diabetes 2015; 64:
2513–2525.
19. Kokkinos A, Le Roux CW, Alexiadou K, et al. Eating slowly increases the
postprandial response of the anorexigenic gut hormones, peptide YY and
glucagon-like peptide-1. J Clin Endocrinol Metab 2010; 95: 333–337.
Meek et al. 115
20. Kuhre RE, Wewer Albrechtsen NJ, Hartmann B, et al. Measurement of
the incretin hormones: glucagon-like peptide-1 and glucose-dependent
insulinotropic peptide. J Diabetes Complications 2015; 29: 445–450.
21. MercodiaGlucagon ELISA. Directions for use, 2013. Available at: https://
www.mercodia.com/product/glucagon-elisa/#prod-info-3 (accessed 23
November 2020).
22. Sleddering MA, Bakker LE, Janssen LG, et al. Higher insulin and
glucagon-like peptide-1 (GLP-1) levels in healthy, young South Asians
as compared to Caucasians during an oral glucose tolerance test.
Metabolism 2014; 63: 226–232.
23. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal
size and body weight in healthy subjects and people with type 1 and type 2
diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706–2713.
24. Alsalim W, Omar B, Pacini G, et al. Incretin and islet hormone responses
to meals of increasing size in healthy subjects. J Clin Endocrinol Metab
2015; 100: 561–568.
25. Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates
glucagon secretion, enhances lipid absorption, and inhibits gastric acid
secretion in humans. Gastroenterology 2006; 130: 44–54.
26. Christensen M, Vedtofte L, Holst JJ, et al. Glucose-dependent insulino-
tropic polypeptide: a bifunctional glucose-dependent regulator of glucagon
and insulin secretion in humans. Diabetes 2011; 60: 3103–3109.
27. Lund A, Bagger JI, Wewer Albrechtsen NJ, et al. Evidence of extrapancre-
atic glucagon secretion in man. Diabetes 2016; 65: 585–597.
28. Jorsal T, Wewer Albrechtsen NJ, Christensen MM, et al. Investigating
intestinal glucagon after roux-en-Y gastric bypass surgery. J Clin
Endocrinol Metab 2019; 104: 6403–6416.
29. Færch K, Vistisen D, Pacini G, et al. Insulin resistance is accompanied by
increased fasting glucagon and delayed glucagon suppression in individu-
als with normal and impaired glucose regulation. Diabetes 2016; 65:
3473–3481.
30. Roberts GP, Kay RG, Howard J, et al. Gastrectomy with Roux-en-Y
reconstruction as a lean model of bariatric surgery. Surg Obes Relat Dis
2018; 14: 562–568.
31. Kobayashi M, Waki H, Nakayama H, et al. Pseudo-hyperglucagonemia
was observed in the pancreatectomized cases when measured by glucagon
sandwich ELISA. J Diabetes Investig. Epub ahead of print 18 June 2020.
doi: 10.1111/jdi.13325.
32. Roberts GP, Larraufie P, Richards P, et al. Comparison of human and
murine enteroendocrine cells by transcriptomic and peptidomic profiling.
Diabetes 2019; 68: 1062–1072.
116 Annals of Clinical Biochemistry 58(2)
